Arie Belldegrun, M.D. – Chairman
Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr. Belldegrun has been closely involved with the founding, development and sale of several private and public biopharmaceutical companies. In 1996 he founded Agensys, and served as its founding Chairman of the board of directors. Dr. Belldegrun was also the founding vice-chairman of the board of directors and chairman of the scientific advisory board of Cougar Biotechnology that was acquired by Johnson & Johnson in 2009 in a $970 million transaction.
Dr. Belldegrun also serves as chairman and partner of Two River Group, a New York–based venture capital firm and merchant bank focusing on building biotechnology companies. He is Chairman of Arno Therapeutics, Inc. and a Director of Nile Therapeutics, Inc., two portfolio companies of Two River Group. Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate fellowship at the Weizmann Institute of Science and his residency in Urological Surgery at Harvard Medical School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He has authored more than 400 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons (AAGUS). Dr. Belldegrun’s laboratory has developed GM-CAIX and related products and has published extensively on the potential of CAIX in cancer therapy.
David Bonderman is a founding partner of TPG. TPG generally makes significant investments in operating companies through acquisitions and restructurings across a broad range of industries throughout the United States, Europe and Asia.
TPG and its affiliates have approximately $48 billion of capital under management. Portfolio companies controlled by TPG have combined revenues of over $85 billion, operate in more than 130 countries and employ approximately 600,000 people. Among the portfolio companies of TPG are: PETCO; IMS Health; Avaya; Harrah’s Entertainment, Energy Future Holdings (TXU); Neiman Marcus; SunGard and Univision.
Prior to forming TPG in 1992, Mr. Bonderman was Chief Operating Officer of the Robert M. Bass Group, Inc. (now doing business as Keystone Group, L.P.) in Fort Worth, Texas. Prior to joining RMBG in 1983, Mr. Bonderman was a partner in the law firm of Arnold & Porter in Washington, D.C., where he specialized in corporate, securities, bankruptcy and antitrust litigation. From 1969 to 1970, Mr. Bonderman was a Fellow in Foreign and Comparative Law in conjunction with Harvard University and from 1968 to 1969; he was Special Assistant to the U.S. Attorney General in the Civil Rights Division. From 1967 to 1968, Mr. Bonderman was Assistant Professor at Tulane University School of Law in New Orleans.
Mr. Bonderman graduated Magna Cum Laude from Harvard Law School in 1966. He was a member of the Harvard Law Review and a Sheldon Fellow. He is a 1963 graduate of the University of Washington in Seattle. Mr. Bonderman serves on the Boards of the following public companies: Armstrong Worldwide Industries, Inc.; CoStar Group, Inc.; General Motors Company; and Ryanair Holdings, plc, of which he is Chairman. He also serves on the Boards of The Wilderness Society, the Grand Canyon Trust, The University of Washington Foundation and the American Himalayan Foundation.
Farah Champsi is a Managing Director
at Alta partners, which is joined in 2000. She currently
serves also on the board of directors of Allakos, Chimerix,
Portola Pharmaceuticals and Trevena. Farah also led Alta's
investments in Achaogen, Agensys, Cytokinetics, Esperion
Therapeutics, Excaliard Pharmaceuticals, Orphan Medical, and
Prior to Alta, Farah was an
investment banker at Robertson Stephens & Company between
1987 and 1999, where she focused on biotechnology and other
life sciences companies. She was elected a General Partner
in 1992 and head of the global life sciences investment
banking group in 1995. During that time, she was responsible
for building one of the most successful life sciences
investment banking franchises on Wall Street.
She holds a Master of Business
Administration from Stanford University and a Bachelor of
Arts in Economics from Smith College.
Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. He was active in the formation of UCLA’s California NanoSystems Institute and serves as Co-Chairman of the Zhejiang California NanoSystems Institute in China. Roy is Vice Chairman of the first joint venture bank in the PRC, Xiamen International Bank and has been involved with numerous financial institutions as Founder, Chairman and Director. He also assisted in the formation of Agensys and served on its Board of Directors. Roy is a member of RAND’s Center for Asia Pacific Policy’s advisory board, Chairman of the Pacific Pension Institute’s advisory board and serves on the UCLA Foundation’s investment committee.
Joshua A. Kazam
Mr. Kazam is a co-founder and Partner of Two River. He currently serves as Vice President of Two River's managing member and also serves as an Officer and Director of Riverbank Capital Securities, Inc., a FINRA member broker dealer ("Riverbank"). Prior to co-founding Two River, he was employed by a venture capital firm specializing in biotechnology investments, where he most recently served as Managing Director and was responsible for ongoing operations of venture investments. In addition, Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a New York based private equity fund focused on biotechnology investments.
Mr. Kazam received his degree in entrepreneurial management from the Wharton School of the University of Pennsylvania.
Mr. Ran Nussbaum is a managing partner and the co-founder of
The Pontifax Group, who has established three funds with
over $220M under management and over 30 portfolio companies.
Over the past ten years, Ran has been managing the group's
activity alongside Mr. Tomer Kariv. He also served as CEO of
Biomedix and Spearhead Ltd. as well as Nasvax's Chairman of
Ran's real life experience in the life sciences arena
coupled with a 10-year experience in the business
intelligence field create a unique blend of skills, enabling
him to support companies from inception to
commercialization. His work revolves around constant and
active involvement in companies, providing them with
strategic and business development oversight. Ran serves as
a board member of many of the group's portfolio companies
including, c-CAM, Insuline (public co.), Eloxx, Bioblast,
Theracaot, CollPlant (public), Protab, Quiet, Fusimab Ltd
and as Ocon chairman of the board.
Mr. Ruchefsky is President of Commercial Street Capital
LLC, a private investment company and significant
stockholder in Kite Pharma. For the last decade, Mr.
Ruchefsky has been working as a private investment manager
for the founder and CEO of a multi-billion dollar hedge
fund. Mr. Ruchefsky began his career at a prominent New York
City law firm where he became a partner, member of
management and chair of a specialized litigation group. Upon
leaving his law firm and prior to his current employment,
Mr. Ruchefsky was a principal of an early stage venture
capital operation. Mr. Ruchefsky currently sits on the
boards of several public and private companies, including
Arno Therapeutics Inc. and Itamar Medical.
Mr. Ruchefsky is a graduate of The George Washington
University Law School.